| Trial of Antimicrobials Versus Placebo in Addition to Fecal Transplant Therapy in Ulcerative Colitis (NCT02606032) | Hamilton Health Sciences Corporation | 2016-05-01 |
| The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis (NCT02721719) | University of British Columbia | 2016-05-01 |
| The Belgian SMART Study Evaluating the Use of Golimumab for Ulcerative Colitis (NCT02914717) | Universitaire Ziekenhuizen KU Leuven | 2016-04-27 |
| Patient-Centred Innovations for Persons With Multimorbidity - Quebec (NCT02789800) | Université de Sherbrooke | 2016-04-22 |
| Reduced Sulfur Diet in Ulcerative Colitis Patients (NCT04474561) | University of Calgary | 2016-04-20 |
| A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerative Colitis (UC), and Participants With Crohn's Disease (CD) (NCT02749630) | Genentech, Inc. | 2016-04-11 |
| Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE) (NCT02750800) | AbbVie | 2016-04-07 |
| Linked Color Imaging vs. White Light for Colorectal Dysplasia in Ulcerative Colitis (NCT02772406) | Affiliated Hospital to Academy of Military Medical Sciences | 2016-04-01 |
| Body Composition in Children With Inflammatory Bowel Disease (NCT02745457) | Schneider Children's Medical Center, Israel | 2016-04-01 |
| Randomized Controlled Trial of Stress Reduction and Lifestyle Modification for Ulcerative Colitis (NCT02721823) | Universität Duisburg-Essen | 2016-03-01 |
| Safety and Pharmacokinetic Study of LYC-30937 in Subjects With Active Ulcerative Colitis (NCT02818543) | Lycera Corp. | 2016-03-01 |
| Improving the Quality of Care for Adults With Inflammatory Bowel Disease (NCT02791854) | Dartmouth-Hitchcock Medical Center | 2016-02-26 |
| Interest of Propionibacterium Freudenreichii for the Treatment of Mild to Moderate Ulcerative Colitis (NCT02488954) | Rennes University Hospital | 2016-02-12 |
| Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC) (NCT02522780) | Ferring Pharmaceuticals | 2016-02-01 |
| Bio-enhanced Curcumin as an Add-on Treatment in Maintaining Remission of Ulcerative Colitis (NCT02683759) | Asian Institute of Gastroenterology, India | 2016-02-01 |
| Azathioprine Based on Endoscopy After Clinical Remission in Moderate to Severe Ulcerative Colitis (NCT02579733) | Kyungpook National University Hospital | 2016-02-01 |
| Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis (NCT02536404) | Arena Pharmaceuticals | 2016-01-25 |
| A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis (NCT02618187) | Seres Therapeutics, Inc. | 2016-01-13 |
| Patient-Centred Innovations for Persons With Multimorbidity - Ontario (NCT02742597) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2016-01-12 |
| Predictive Factors of Endoscopic Mucosal Healing in Quiescent Ulcerative Colitis (NCT02640391) | Kyungpook National University Hospital | 2016-01-01 |
| Phenotyping IBS: Perceptions and Modulations of Visceral Sensations (NCT02693730) | University of California, Los Angeles | 2016-01-01 |
| PET Combined With MRI for Monitoring Inflammatory Activity in Patients With Ulcerative Colitis (NCT03781284) | Universität Duisburg-Essen | 2016-01-01 |
| In Vivo Molecular Imaging Predicts Therapeutic Response in Ulcerative Colitis (NCT02852850) | Shandong University | 2016-01-01 |
| Evaluation of Early Mucosal Healing During Clinical Remission in Pediatric Ulcerative Colitis (NCT03179865) | Wolfson Medical Center | 2016-01-01 |
| A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis (NCT02589665) | Eli Lilly and Company | 2015-12-09 |
| An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis (NCT02531126) | Celgene | 2015-12-02 |
| Fecal Microbiome Transplant (NCT02636517) | Judith Kelsen | 2015-12-01 |
| Effectiveness of Cortiment® in Patients With Ulcerative Colitis (NCT02586259) | Ferring Pharmaceuticals | 2015-12-01 |
| Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis (NCT02632175) | AbbVie | 2015-11-26 |
| Pediatric FEcal Microbiota Transplant for Ulcerative Colitis (NCT02487238) | McMaster Children's Hospital | 2015-11-01 |
| Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis (NCT02330653) | Stacy A. Kahn | 2015-11-01 |
| Effect of UGIR in Adults With Compromised Gut Function and Malabsorption (NCT03011593) | Metagenics, Inc. | 2015-11-01 |
| Multispectral Optoacoustic Tomography (MSOT) for the Evaluation of Disease Activity in Inflammatory Bowel Diseases (IBD) (NCT02622139) | University of Erlangen-Nürnberg Medical School | 2015-11-01 |
| Complications and Outcomes of Pouch Excision (NCT03952195) | Icahn School of Medicine at Mount Sinai | 2015-11-01 |
| Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis (NCT02447302) | Arena Pharmaceuticals | 2015-10-15 |
| Integrative Gastroenterology - an Observational Trial (NCT02476643) | Universität Duisburg-Essen | 2015-10-01 |
| Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC) (NCT02522767) | Ferring Pharmaceuticals | 2015-10-01 |
| Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis (NCT02520284) | Gilead Sciences | 2015-09-01 |
| Amino Acids in Ileal Pouch-anal Anastomosis for Ulcerative Colitis (NCT02084550) | Aarhus University Hospital | 2015-09-01 |
| Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study (NCT02542917) | King's College Hospital NHS Trust | 2015-09-01 |
| Characterization of CD Responders to Vedolizumab (NCT04909359) | University of Miami | 2015-08-25 |
| Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis (NCT02506179) | AbbVie | 2015-08-18 |
| Autoimmune Paradoxical Reactions in IBD Longitudinal Cohort (NCT02503514) | University of North Carolina, Chapel Hill | 2015-08-01 |
| Safety and Efficacy of QBECO in Moderate to Severe Ulcerative Colitis (NCT02426372) | Qu Biologics Inc. | 2015-07-01 |
| Fecal Microbiota Transplantation as a Treatment for Ulcerative Colitis (NCT04434872) | Tel-Aviv Sourasky Medical Center | 2015-07-01 |
| Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis (NCT02435992) | Celgene | 2015-06-17 |
| A Prospective Non-interventional Multicenter Study to Evaluate the Effectiveness of Adalimumab in Korean Patients With Ulcerative Colitis (UC) and Identify Potential Predictors of Clinical Response in Routine Clinical Practice (NCT02499263) | AbbVie | 2015-06-11 |
| The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness (NCT02423512) | Icahn School of Medicine at Mount Sinai | 2015-06-01 |
| The Value of I-Scan and Confocal Laser Endomicroscopy for the Assessment of Chronic Inflammatory Bowel Disease (NCT02481687) | University of Medicine and Pharmacy Craiova | 2015-06-01 |
| Medication Adherence in Patients With Inflammatory Bowel Disease (IBD) (NCT02620514) | Emory University | 2015-06-01 |
| Study for Safety and Tolerability of TOP1288 Administered Rectally in Healthy and Ulcerative Colitis Subjects (NCT02463045) | Topivert Pharma Ltd | 2015-05-01 |
| Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator (NCT02413047) | Indiana University | 2015-05-01 |
| Efficacy of Fecal Microbiota Transplantation for Inflammatory Bowel Disease (NCT02575040) | Saglik Bilimleri Universitesi Gulhane Tip Fakultesi | 2015-05-01 |
| Threonine Requirement in IBD Adults and Healthy Adult Controls (NCT02423460) | Société des Produits Nestlé (SPN) | 2015-05-01 |
| Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Active Ulcerative Colitis (NCT02442037) | Affiliated Hospital to Academy of Military Medical Sciences | 2015-05-01 |
| SSAT 054: Non Genetic Factors in the Pathogenesis of IBD in Twins (NCT02383953) | St Stephens Aids Trust | 2015-05-01 |
| The Study of Efficacy and Mechanism in Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis (NCT02435160) | Jun Liu | 2015-05-01 |
| Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease (NCT02539368) | Pfizer | 2015-04-22 |
| Assessment of CMV-specific ELISPOT Assay for Predicting CMV Colitis in Patient With Ulcerative Colitis (NCT02439372) | Asan Medical Center | 2015-04-01 |
| Evaluation of 3D Visualization for Total Colectomy (NCT02370056) | The Cleveland Clinic | 2015-03-01 |
| An Efficacy and Safety Study of PENTASA in Chinese Patients With Left-sided Active Ulcerative Colitis Followed by a 24-Week Open-Label Extension Phase (NCT02368717) | Ferring Pharmaceuticals | 2015-03-01 |
| Long-term Outcome of Patients With Acute Ulcerative Colitis After First Course of Intravenous Corticosteroids (NCT04564638) | Tampere University Hospital | 2015-03-01 |
| Diet Study on Ulcerative Colitis (NCT04147598) | University of Miami | 2015-02-25 |
| Low Dose IL-2 for Ulcerative Colitis (NCT02200445) | Scott B. Snapper, MD PHD | 2015-02-01 |
| Trial on Impact of HealthPROMISE Mobile App on Inflammatory Bowel Disease Care and Quality of Life (NCT02322307) | Icahn School of Medicine at Mount Sinai | 2015-02-01 |
| Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis (NCT02289417) | Amgen | 2015-01-08 |
| Standardized Fecal Microbiota Transplantation for Inflammatory Bowel Disease (NCT02335281) | Yanling Wei | 2015-01-01 |
| Induction and Maintenance of Remission With Pentasa as Ulcerative Colitis Treatment (NCT02261636) | Ferring Pharmaceuticals | 2015-01-01 |
| A Retrospective Analysis: the Influence of Caltrate Supplement on the Effect of Mesalazine in Ulcerative Colitis (NCT04276649) | Second Affiliated Hospital of Wenzhou Medical University | 2015-01-01 |
| Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis (NCT03441893) | Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan | 2015-01-01 |
| Thermography in Surveillance of Ulcerative Colitis (NCT02149043) | University Hospital Dubrava | 2015-01-01 |
| A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors (NCT02136069) | Hoffmann-La Roche | 2014-12-24 |
| Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis (NCT02093663) | Shire | 2014-12-12 |
| To Evaluate the Safety and Efficacy of Remsima™ in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC) (NCT02326155) | Celltrion | 2014-12-08 |
| Evaluating Safety and Efficacy of Herbal Treatment in Ulcerative Colitis (NCT02442960) | Stanford University | 2014-12-01 |
| Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative Colitis (NCT02337608) | Lakefront Biotherapeutics NV | 2014-12-01 |
| A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (NCT02171429) | Hoffmann-La Roche | 2014-11-14 |
| A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (NCT02163759) | Hoffmann-La Roche | 2014-11-04 |
| The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (NCT02361957) | Wageningen University | 2014-11-01 |
| Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis (NCT02065557) | AbbVie | 2014-10-13 |
| Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study (NCT02266849) | Odense University Hospital | 2014-10-01 |
| Influence of Aerobic Exercise Training (AET) on Inflammatory Bowel Disease (IBD) in Children and Adolescents (NCT02264275) | University of Basel | 2014-10-01 |
| The NOR-SWITCH Study (NCT02148640) | Diakonhjemmet Hospital | 2014-10-01 |
| Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies (NCT02118584) | Hoffmann-La Roche | 2014-09-15 |
| Vascular Dysfunction in Paediatric IBD (NCT02161640) | Great Ormond Street Hospital for Children NHS Foundation Trust | 2014-09-01 |
| Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD (NCT02197780) | University Medical Center Groningen | 2014-09-01 |
| Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD). (NCT02265588) | Erasmus Medical Center | 2014-09-01 |
| Study of the Pharmacokinetics of Golimumab in Moderate to Severe Ulcerative Colitis (NCT02277470) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2014-08-01 |
| Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis (NCT02142725) | Dr. Falk Pharma GmbH | 2014-07-21 |
| Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) (NCT02155335) | Merck Sharp & Dohme LLC | 2014-07-01 |
| Fecal Microbiota Transplantation (FMT) in the Management of Active Ulcerative Colitis (NCT02227342) | University of Alberta | 2014-07-01 |
| Treatment With the Specific Carbohydrate Diet for Children With Active Crohns Disease and Ulcerative Colitis (NCT02213835) | David Suskind | 2014-06-01 |
| Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab (NCT02186886) | Kliniken im Naturpark Altmuehltal | 2014-06-01 |
| German Colon Capsule Registry (NCT02182466) | Johann Wolfgang Goethe University Hospital | 2014-06-01 |
| Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) (NCT02092285) | Merck Sharp & Dohme LLC | 2014-05-09 |
| Care Path for the Management of Ulcerative Colitis (NCT01882426) | University of Western Ontario, Canada | 2014-05-01 |
| Evaluation of PillCam IBD Capsule Endoscopy System in Visualization of Lesions in the Colon Indicative of Ulcerative Colitis Disease (NCT02025777) | Medtronic - MITG | 2014-05-01 |
| Evaluation of Health Costs and Resource Utilization (NCT01960426) | University of Western Ontario, Canada | 2014-04-01 |
| Comparison of PillCamCOLON (C2) Capsule and Standard Endoscopy for the Evaluation of Patients With Ulcerative Colitis (NCT02610569) | Dr. Arnaud Bourreille | 2014-04-01 |
| Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease (NCT02913508) | Takeda | 2014-04-01 |